These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 3394585)
1. Inhibition of passive cutaneous anaphylaxis by several histamine (H1) and serotonin antagonists in the rat. Metys J; Frycová H; Soucek R Agents Actions; 1988 Apr; 23(3-4):331-3. PubMed ID: 3394585 [TBL] [Abstract][Full Text] [Related]
2. LC-6 inhibition of the rat skin reactions is due to mediator release inhibitor and not to mediator antagonism. Hurtado I; Urbina C Acta Cient Venez; 1983; 34(1):44-7. PubMed ID: 6424369 [No Abstract] [Full Text] [Related]
3. [Anti-allergic properties of pipethiaden--a new preventive agent for migraine]. Frycová H; Metys J Cesk Farm; 1989 Jul; 38(6):264-8. PubMed ID: 2790993 [TBL] [Abstract][Full Text] [Related]
4. Anti-allergic effects of ketanserin on animal models of allergic reactions. Nagai H; Suda H; Kitagaki K; Goto S; Miura T; Koda A Arch Int Pharmacodyn Ther; 1990; 307():172-82. PubMed ID: 1710442 [TBL] [Abstract][Full Text] [Related]
5. In vivo anti-allergic and bronchopulmonary pharmacology of REV 3164 in rats and guinea-pigs. Leibowitz M; Gordon RJ; Wolf PS; Sonnino-Goldman P Arch Int Pharmacodyn Ther; 1984 Sep; 271(1):135-54. PubMed ID: 6497506 [TBL] [Abstract][Full Text] [Related]
6. Participation of histamine H1 and H2 receptors in passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. Inagaki N; Nakamura N; Nagao M; Musoh K; Kawasaki H; Nagai H Eur J Pharmacol; 1999 Feb; 367(2-3):361-71. PubMed ID: 10079012 [TBL] [Abstract][Full Text] [Related]
7. The effects of serotonin antagonists in a behavioral despair procedure in mice. Luttinger D; Freedman M; Hamel L; Ward SJ; Perrone M Eur J Pharmacol; 1984 Dec; 107(1):53-8. PubMed ID: 6526071 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of passive cutaneous anaphylaxis (PCA) by azelastine: dissociation of its antiallergic activities from antihistaminic and antiserotonin properties. Chand N; Harrison JE; Rooney SM; Sofia RD; Diamantis W Int J Immunopharmacol; 1985; 7(6):833-8. PubMed ID: 3935586 [TBL] [Abstract][Full Text] [Related]
9. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995 [TBL] [Abstract][Full Text] [Related]
10. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413). Fukuda T; Saito T; Tajima S; Shimohara K; Ito K Arzneimittelforschung; 1984; 34(7):805-10. PubMed ID: 6208915 [TBL] [Abstract][Full Text] [Related]
11. Levocabastine: pharmacological profile of a highly effective inhibitor of allergic reactions. Awouters F; Niemegeers CJ; Jansen T; Megens AA; Janssen PA Agents Actions; 1992 Jan; 35(1-2):12-8. PubMed ID: 1354927 [TBL] [Abstract][Full Text] [Related]
12. A method for evaluating anti-allergic drugs by simultaneously induced passive cutaneous anaphylaxis and mediator cutaneous reactions. Koda A; Miura T; Inagaki N; Sakamoto O; Arimura A; Nagai H; Mori H Int Arch Allergy Appl Immunol; 1990; 92(3):209-16. PubMed ID: 1703513 [TBL] [Abstract][Full Text] [Related]
13. Ketotifen: a histamine release inhibitor. Martin U; Roemer D Monogr Allergy; 1977; 12():145-9. PubMed ID: 72350 [No Abstract] [Full Text] [Related]
14. Pharmacological characterization of mouse ear PCA. Inagaki N; Goto S; Nagai H; Koda A Int Arch Allergy Appl Immunol; 1985; 78(2):113-7. PubMed ID: 2864316 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of allergic reactions by a new antiallergic drug, LC-6 (trans-2,3b,4,5,7,8b,9,10-octahydronaphthol[1,2-c:5,6-c'] dipyrazole). I. Inhibition of the rat reaginic passive cutaneous anaphylaxis. Hurtado I; Márquez VE; Vítolo MJ Int Arch Allergy Appl Immunol; 1978; 57(6):507-13. PubMed ID: 28295 [TBL] [Abstract][Full Text] [Related]
16. Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. McLeod RL; Mingo GG; Kreutner W; Hey JA Life Sci; 2005 Mar; 76(16):1787-94. PubMed ID: 15698856 [TBL] [Abstract][Full Text] [Related]
17. The effects of H1 and H2 receptor antagonism on the response of monkey skin to intradermal histamine, reverse-type anaphylaxis, and passive cutaneous anaphylaxis. Hutchcroft BJ; Moore EG; Orange RP J Allergy Clin Immunol; 1979 Jun; 63(6):376-82. PubMed ID: 36420 [TBL] [Abstract][Full Text] [Related]
18. Serotonin type 2 antagonists inhibit lordosis behavior in the female rat: reversal with quipazine. Mendelson SD; Gorzalka BB Life Sci; 1986 Jan; 38(1):33-9. PubMed ID: 2934598 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous vascular permeability factors (histamine, 5-hydroxytryptamine, bradykinin) and passive cutaneous anaphylaxis in sheep. Eyre P J Pharm Pharmacol; 1970 Feb; 22(2):104-9. PubMed ID: 4392243 [No Abstract] [Full Text] [Related]
20. In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. Van Wauwe J; Awouters F; Neimegeers CJ; Janssens F; Van Nueten JM; Janssen PA Arch Int Pharmacodyn Ther; 1981 May; 251(1):39-51. PubMed ID: 6114717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]